Tekla Life Sciences Investors (HQL) 10-Year Financial Performance & Capital Metrics

HQL • • Banking & Credit

Financial ServicesAsset ManagementSpecialized & Niche Asset ManagersSector & Commodity Specialists

AboutTekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.Show more

Net Interest Income $204K +308.1%
Total Revenue $39M +23.6%
Net Income $22M +121.4%
Return on Equity 5.59% +124.6%
Net Interest Margin 0.05% +320.4%
Efficiency Ratio 2.97% -29.9%
ROA 5.47% +124.8%
Equity / Assets 99.83% +4.1%
Book Value per Share 14.21 -8.3%
Tangible BV/Share 14.21 -8.3%
Debt/Equity -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Efficient operations: 3.0% efficiency ratio
✓Well capitalized: 99.8% equity/assets
✓Diversified revenue: 99.5% from non-interest income
✓Trading at only 1.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak NIM of 0.1%
✗Shares diluted 10.2% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y54.24%

5Y81.75%

3Y0.27%

TTM-

Profit (Net Income) CAGR

10Y-12.47%

5Y-4.85%

3Y-43.37%

TTM-165.59%

EPS CAGR

10Y-17.84%

5Y-9.2%

3Y-46.5%

TTM-153.41%

ROCE

10Y Avg1.22%

5Y Avg3.36%

3Y Avg-3.63%

Latest-1.28%

Peer Comparison

Sector & Commodity Specialists

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NHICNewHold Investment Corp III	216.79M	10.37	515.92			1.6%
PLTSPlatinum Analytics Cayman Limited Class A Ordinary Shares	196.1M	17.50	245.10	280.21%	35.16%
SOLSSolstice Advanced Materials Inc.	9.6B	60.51	22.75	3.32%	11.19%	13.59%	5.68%	0.13
HQLTekla Life Sciences Investors	491.34M	16.60	21.01	23.61%	56.75%	-13.43%
SWKHSWK Holdings Corporation	211.44M	17.48	16.19	19.14%	29.98%	8.94%	10.84%	0.13
BURBurford Capital Limited	2.15B	9.83	14.89	-56.23%	31.02%	2.7%	10.04%	0.55
ASAASA Gold and Precious Metals Limited	1.2B	63.48	10.48	9.47%	96.94%	39.78%
STKESol Strategies Inc. Common Shares	64.53M	2.30	7.19			-4.25%

Profit & Loss

	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023
Net Interest Income+	0	0	0	90.56K	0	0	164.8K	0	50.09K	204.45K
NII Growth %	-	-	-	-	-1%	-	-	-1%	-	3.08%
Net Interest Margin %	-	-	-	-	-	-	-	-	-	-
Interest Income	0	0	0	90.56K	0	0	164.8K	0	50.09K	204.45K
Interest Expense	93.03M	45.22M	0	0	0	0	0	0	0	0
Loan Loss Provision	-88.89M	-39.57M	4.95M	4.61M	0	0	5.21M	6.08M	5.55M	5.24M
Non-Interest Income+	876.79K	1.32M	6.29M	69.72M	1.99M	2.44M	38.91M	45.02M	31.81M	39.18M
Non-Interest Income %	-	-	-	-	-	-	-	-	-	-
Total Revenue+	876.79K	1.32M	6.29M	69.81M	1.99M	2.44M	39.07M	45.02M	31.86M	39.39M
Revenue Growth %	0.7%	0.51%	3.76%	10.1%	-0.97%	0.23%	15.01%	0.15%	-0.29%	0.24%
Non-Interest Expense	88.39M	39.18M	13.35M	1.26M	5.59M	5.32M	1.03M	1.16M	1.35M	1.17M
Efficiency Ratio	-	-	-	-	-	-	-	-	-	-
Operating Income+	-3.77M	-4.72M	-3.79M	-3.88M	-3.61M	-2.88M	123.05M	64.53M	-104.6M	-5.24M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.19%	-0.25%	0.2%	-0.02%	0.07%	0.2%	43.74%	-0.48%	-2.62%	0.95%
Pretax Income+	89.27M	40.5M	-11.91M	68.56M	28.66M	-70.48M	123.05M	64.53M	-104.6M	22.35M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	3	0	0	0	0	0	0
Effective Tax Rate %	-	-	-	-	-	-	-	-	-	-
Net Income+	89.27M	40.5M	-11.91M	68.56M	28.66M	-70.48M	123.05M	64.53M	-104.6M	22.35M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	0.05%	-0.55%	-1.29%	6.76%	-0.58%	-3.46%	2.75%	-0.48%	-2.62%	1.21%
Net Income (Continuing)	89.27M	40.5M	-11.91M	68.56M	28.66M	-70.48M	123.05M	64.53M	-104.6M	22.35M
EPS (Diluted)+	4.70	2.06	-0.57	3.21	1.28	-3.04	5.16	2.66	-4.07	0.79
EPS Growth %	-0.17%	-0.56%	-1.28%	6.63%	-0.6%	-3.38%	2.7%	-0.48%	-2.53%	1.19%
EPS (Basic)	4.70	2.06	1.00	3.21	1.28	-3.04	5.16	2.66	-4.07	0.79
Diluted Shares Outstanding	19.01M	19.69M	20.74M	21.36M	22.41M	23.18M	23.85M	24.26M	25.68M	28.29M

Balance Sheet

	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023
Cash & Short Term Investments+	2.34K	403	1000K	615.31K	0	1000K	1000K	990	445	1000K
Cash & Due from Banks	2.34K	403	10.07K	615.31K	0	1.12M	-4.97M	990	445	477
Short Term Investments	0	0	1000K	0	0	0	1000K	0	0	1000K
Total Investments+	440.09M	443.83M	9.85M	466.98M	466.45M	381.47M	488.94M	534.01M	414.08M	412.77M
Investments Growth %	0.49%	0.01%	-0.98%	46.39%	-0%	-0.18%	0.28%	0.09%	-0.22%	-0%
Long-Term Investments	440.09M	443.83M	370.84M	466.98M	466.45M	381.47M	483.97M	534.01M	414.08M	397.53M
Accounts Receivables	595.1K	1000K	1000K	0	1000K	1000K	0	150.34K	623.47K	1000K
Goodwill & Intangibles+	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
PP&E (Net)	0	0	0	0	0	0	0	0	0	0
Other Assets	-257	2.31M	26.67M	-466.98M	-466.45M	0	0	0	0	0
Total Current Assets	4.76M	21.72M	20.12M	633.44K	11.19M	5.09M	73.9K	144.66K	623.92K	5.05M
Total Non-Current Assets	440.09M	446.14M	397.51M	466.98M	466.45M	381.47M	483.97M	534.01M	414.08M	397.53M
Total Assets+	444.84M	467.85M	417.63M	468.33M	478.47M	386.98M	484.17M	534.19M	414.73M	402.6M
Asset Growth %	0.47%	0.05%	-0.11%	0.12%	0.02%	-0.19%	0.25%	0.1%	-0.22%	-0.03%
Return on Assets (ROA)	0.24%	0.09%	-0.03%	0.15%	0.06%	-0.16%	0.28%	0.13%	-0.22%	0.05%
Accounts Payable	140.62K	4.21M	2.1M	1.31M	2.35M	2.82M	0	150.34K	5.1M	0
Total Debt+	0	0	0	0	0	0	26.03K	1.34M	11.09M	0
Net Debt	-2.34K	-403	-10.07K	-615.31K	0	-1.12M	4.99M	1.34M	10.65K	-477
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Short-Term Debt	0	0	0	0	0	0	13.94K	10.04M	11.09M	0
Other Liabilities	0	0	0	0	0	0	13.94K	10.75M	11.72M	666.96K
Total Current Liabilities	754.55K	5.01M	2.66M	1.31M	2.35M	2.82M	581.24K	10.75M	5.1M	0
Total Non-Current Liabilities	0	0	2.66M	1.98M	2.98M	3.33M	13.94K	10.75M	11.72M	666.96K
Total Liabilities	754.55K	5.01M	2.66M	1.98M	2.98M	2.82M	595.18K	10.75M	16.82M	666.96K
Total Equity+	444.09M	462.84M	414.97M	466.35M	475.49M	383.65M	483.57M	523.44M	397.9M	401.93M
Equity Growth %	0.47%	0.04%	-0.1%	0.12%	0.02%	-0.19%	0.26%	0.08%	-0.24%	0.01%
Equity / Assets (Capital Ratio)	-	-	-	-	-	-	-	-	-	-
Return on Equity (ROE)	0.24%	0.09%	-0.03%	0.16%	0.06%	-0.16%	0.28%	0.13%	-0.23%	0.06%
Book Value per Share	23.37	23.51	20.01	21.84	21.22	16.55	20.28	21.58	15.49	14.21
Tangible BV per Share	-	-	-	-	-	-	-	-	-	-
Common Stock	262.95M	281.46M	301.31M	317.62M	333.78M	345.29M	238.83K	246.68K	256.8K	267.91K
Additional Paid-in Capital	0	0	0	0	0	0	356.3M	372.49M	388.1M	403.15M
Retained Earnings	181.13M	181.38M	-2.73M	-22.5K	141.71M	38.36M	127.03M	150.7M	9.55M	-1.48M
Accumulated OCI	0	0	116.39M	148.73M	0	0	0	0	0	0
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Preferred Stock	0	0	0	22.5K	0	0	0	0	0	0

Cash Flow

	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023
Cash from Operations+	-52.56K	0	0	0	0	0	0	0	0	0
Operating CF Growth %	-6.55%	1%	-	-	-	-	-	-	-	-
Net Income	89.27K	40.5K	-11.91K	68.56K	28.66K	-70.48K	123.05K	64.53K	-104.6K	22.35M
Depreciation & Amortization	0	0	0	0	0	0	0	0	0	0
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-141.77K	-40.5K	11.91K	-68.56K	-28.66K	70.48K	-123.05K	-64.53K	104.6K	-22.35M
Working Capital Changes	-65	0	0	0	0	0	0	0	0	0
Cash from Investing+	0	0	0	0	0	0	0	0	0	0
Purchase of Investments	0	0	0	0	0	0	0	0	0	0
Sale/Maturity of Investments	0	0	0	0	0	0	0	0	0	0
Net Investment Activity	-	-	-	-	-	-	-	-	-	-
Acquisitions	0	0	0	0	0	0	0	0	0	0
Other Investing	0	0	0	0	0	0	0	0	0	0
Cash from Financing+	52.53K	0	0	0	0	0	0	0	0	0
Dividends Paid	-13.96K	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Stock Issued	0	0	0	0	0	0	0	0	0	0
Net Stock Activity	-	-	-	-	-	-	-	-	-	-
Debt Issuance (Net)	0	0	0	0	0	0	0	0	0	0
Other Financing	66.49K	0	0	0	0	0	0	0	0	0
Net Change in Cash+	-34	0	0	0	0	1.12M	0	0	-545	32
Exchange Rate Effect	0	0	0	0	0	0	0	0	0	0
Cash at Beginning	37	2	0	0	0	41	1.12M	1.12M	990	445
Cash at End	2	2	0	0	0	1.12M	1.12M	0	445	477
Interest Paid	0	0	0	0	0	0	0	0	0	0
Income Taxes Paid	0	0	0	0	0	0	0	0	0	0
Free Cash Flow+	-52.56K	0	0	0	0	0	0	0	0	0
FCF Growth %	-6.55%	1%	-	-	-	-	-	-	-	-

Banking Ratios

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Return on Equity (ROE)	23.92%	8.93%	-2.71%	15.56%	6.09%	-16.41%	28.38%	12.82%	-22.71%	5.59%
Return on Assets (ROA)	23.88%	8.87%	-2.69%	15.48%	6.05%	-16.29%	28.25%	12.67%	-22.05%	5.47%
Net Interest Margin	0%	0%	0%	0.02%	0%	0%	0.03%	0%	0.01%	0.05%
Efficiency Ratio	10081.17%	2962.09%	212.18%	1.8%	281.64%	217.97%	2.64%	2.57%	4.25%	2.97%
Equity / Assets	99.83%	98.93%	99.36%	99.58%	99.38%	99.14%	99.88%	97.99%	95.94%	99.83%
Book Value / Share	23.37	23.51	20.01	21.84	21.22	16.55	20.28	21.58	15.49	14.21
NII Growth	-	-	-	-	-100%	-	-	-100%	-	308.15%
Dividend Payout	0.02%	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Tekla Life Sciences Investors (HQL) has a price-to-earnings (P/E) ratio of 21.0x. This is roughly in line with market averages.

Growth & Financials

Tekla Life Sciences Investors (HQL) grew revenue by 23.6% over the past year. This is strong growth.

Tekla Life Sciences Investors (HQL) reported a net loss of $53.2M for fiscal year 2023.

Dividend & Returns

Tekla Life Sciences Investors (HQL) has a return on equity (ROE) of 5.6%. This is below average, suggesting room for improvement.

Industry Metrics

Tekla Life Sciences Investors (HQL) has a net interest margin (NIM) of 0.1%. NIM has been under pressure due to interest rate environment.

Tekla Life Sciences Investors (HQL) has an efficiency ratio of 3.0%. This is excellent, indicating strong cost control.

← Back to Screener

US Stock Screener

...